Cantargia AB (CANTA) - Total Assets
Based on the latest financial reports, Cantargia AB (CANTA) holds total assets worth Skr358.89 Million SEK (≈ $38.62 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore Cantargia AB cash debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
Cantargia AB - Total Assets Trend (2011–2024)
This chart illustrates how Cantargia AB's total assets have evolved over time, based on quarterly financial data. See CANTA net assets for net asset value and shareholders' equity analysis.
Cantargia AB - Asset Composition Analysis
Current Asset Composition (December 2024)
Cantargia AB's total assets of Skr358.89 Million consist of 96.4% current assets and 3.6% non-current assets.
| Asset Category | Amount (SEK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr0.00 | 19.4% |
| Accounts Receivable | Skr121.79 Million | 71.5% |
| Inventory | Skr0.00 | 0.0% |
| Property, Plant & Equipment | Skr2.31 Million | 1.4% |
| Intangible Assets | Skr3.75 Million | 2.2% |
| Goodwill | Skr0.00 | 0.0% |
Asset Composition Trend (2011–2024)
This chart illustrates how Cantargia AB's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see CANTA market cap overview.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Cantargia AB's current assets represent 96.4% of total assets in 2024, an increase from 84.5% in 2011.
- Cash Position: Cash and equivalents constituted 19.4% of total assets in 2024, down from 80.6% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, a decrease from 15.0% in 2011.
- Asset Diversification: The largest asset category is accounts receivable at 71.5% of total assets.
Cantargia AB Competitors by Total Assets
Key competitors of Cantargia AB based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
Syndax Pharmaceuticals Inc
NASDAQ:SNDX
|
USA | $472.67 Million |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $506.75 Million |
|
Chengdu Kanghua Biological Products
SHE:300841
|
China | CN¥3.94 Billion |
|
Jiangsu Aidea Pharmaceutical Co Ltd
SHG:688488
|
China | CN¥1.84 Billion |
Cantargia AB - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.82 | 2.41 | 29.96 |
| Quick Ratio | 5.82 | 2.41 | 29.96 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Skr293.97 Million | Skr42.22 Million | Skr882.42 Million |
Cantargia AB - Advanced Valuation Insights
This section examines the relationship between Cantargia AB's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.22 |
| Latest Market Cap to Assets Ratio | 0.28 |
| Asset Growth Rate (YoY) | -23.8% |
| Total Assets | Skr170.43 Million |
| Market Capitalization | $47.30 Million USD |
Valuation Analysis
Below Book Valuation: The market values Cantargia AB's assets below their book value (0.28x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Cantargia AB's assets decreased by 23.8% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Cantargia AB (2011–2024)
The table below shows the annual total assets of Cantargia AB from 2011 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | Skr170.43 Million ≈ $18.34 Million |
-23.82% |
| 2023-12-31 | Skr223.71 Million ≈ $24.07 Million |
-52.88% |
| 2022-12-31 | Skr474.80 Million ≈ $51.10 Million |
-20.90% |
| 2021-12-31 | Skr600.24 Million ≈ $64.60 Million |
-35.14% |
| 2020-12-31 | Skr925.51 Million ≈ $99.60 Million |
+457.35% |
| 2019-12-31 | Skr166.06 Million ≈ $17.87 Million |
-3.14% |
| 2018-12-31 | Skr171.44 Million ≈ $18.45 Million |
-37.53% |
| 2017-12-31 | Skr274.45 Million ≈ $29.54 Million |
+477.66% |
| 2016-12-31 | Skr47.51 Million ≈ $5.11 Million |
+51.39% |
| 2015-12-31 | Skr31.38 Million ≈ $3.38 Million |
+55.91% |
| 2014-12-31 | Skr20.13 Million ≈ $2.17 Million |
+404.52% |
| 2013-12-31 | Skr3.99 Million ≈ $429.36K |
+5.70% |
| 2012-12-31 | Skr3.77 Million ≈ $406.20K |
+57.03% |
| 2011-12-31 | Skr2.40 Million ≈ $258.67K |
-- |
About Cantargia AB
Cantargia AB (publ), a biotechnology company, develops pharmaceuticals for treatment of cancer, inflammatory, and autoimmune diseases. The company is developing CAN04 (nadunolimab), an antibody that can bind IL1RAP, which is in phase II clinical trial for the treatment of pancreatic cancer, non-small cell lung cancer, and triple-negative breast cancer; and CAN10, an antibody against IL1RAP, which… Read more